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Abstract
 
Monocyte recruitment to the central nervous system (CNS) is a necessary step in the develop-
ment of pathologic inflammatory lesions in experimental autoimmune encephalomyelitis
(EAE), a murine model of multiple sclerosis. Monocyte chemoattractant protein (MCP)-1, a
potent agonist for directed monocyte migration, has been implicated in the pathogenesis of
EAE. Here we report that deficiency in CC chemokine receptor (CCR)2, the receptor for
MCP-1, confers resistance to EAE induced with a peptide derived from myelin oligodendro-
 
cyte glycoprotein peptide 35–55 (MOGp35–55). CCR2
 
2
 
/
 
2
 
 mice immunized with MOGp35–
55 failed to develop mononuclear cell inflammatory infiltrates in the CNS and failed to increase
CNS levels of the chemokines RANTES (regulated on activation, normal T cell expressed and
secreted), MCP-1, and interferon (IFN)-inducible protein 10 (IP-10) as well the chemokine
receptors CCR1, CCR2, and CCR5. Additionally, T cells from CCR2
 
2
 
/
 
2
 
 immunized mice
 
showed decreased antigen-induced proliferation and production of IFN-
 
g
 
 compared with
wild-type immunized controls, suggesting that CCR2 enhances the T helper cell type 1 im-
mune response in EAE. These data indicate that CCR2 plays a necessary and nonredundant
role in the pathogenesis of EAE.
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Introduction
 
Chemokines are chemotactic cytokines that share impor-
tant structural features and the ability to attract leukocytes.
The regulated interactions of chemokines with their re-
spective cell surface receptors mediate the recruitment of
specific leukocyte subpopulations to sites of inflammation.
The two major families of chemokines are distinguished by
whether the first two of the four cysteine residues are sepa-
rated by one amino acid (CXC, 
 
a
 
-chemokines) or occur
adjacent to each other (CC, 
 
b
 
-chemokines). Whereas
CXC chemokines are chemotactic mainly for neutrophils
and lymphocytes, CC chemokines preferentially attract
monocytes, eosinophils, basophils, and lymphocytes with
variable selectivity. The CC chemokine family includes the
monocyte chemoattractant protein (MCP)-eotaxin sub-
family, containing MCP-1, -2, -3, -4, and -5 as well as eo-
 
taxin, all of which share 
 
z
 
60% identity (1).
MCP-1 is a potent in vivo monocyte chemoattractant
secreted by a variety of cell types in response to proinflam-
matory stimuli (2). Chemotactic and activating functions of
MCP-1 are directed at monocytes, activated T cells, NK
cells, and basophils. MCP-1 binds solely to CC chemokine
receptor (CCR)2, a seven-transmembrane–spanning pro-
tein that is functionally linked to downstream signaling
pathways through heterotrimeric G proteins (3). CCR2 is
expressed on peripheral blood monocytes and activated T
cells (4) and serves as the receptor for five ligands, MCP-1,
-2, -3, -4, and –5 (3).
 
MCP-1 and CCR2 have been implicated in a number
of inflammatory diseases, including multiple sclerosis (MS;
references 5–7), a chronic inflammatory disease of the cen-
tral nervous system (CNS), and experimental autoimmune
encephalomyelitis (EAE), the animal model for MS (8–13).
 
EAE is mediated by activated neuroantigen-specific CD4
 
1
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Th1 cells and is characterized histologically by mononu-
clear cell infiltrates consisting of monocytes and Ag-spe-
cific and nonspecific CD4
 
1
 
 and CD8
 
1
 
 T cells (14). Mono-
cyte recruitment to the CNS is a necessary step for the
development of inflammatory lesions in EAE (15), and
MCP-1 mRNA is upregulated during the acute phase of
disease induced by immunization with myelin oligoden-
drocyte glycoprotein peptide 35–55 (MOGp35–55) or
other encephalitogenic Ags (9, 10). Vaccination of mice
with a naked MCP-1 DNA, resulting in anti–MCP-1 Abs,
inhibited the generation EAE (16). In addition, CCR2 sig-
naling appears to promote Th1 immune responses in vivo
(17–19). Taken together, these data indicate that MCP-1
and CCR2 might play an important role in the initiation
and progression of EAE.
To test the hypothesis that CCR2 signaling is required
for the pathogenesis of EAE, we induced disease in
CCR2
 
2
 
/
 
2
 
 and CCR2
 
1
 
/
 
1
 
 animals with the encephalito-
genic peptide MOGp35–55. We found that mice lacking
CCR2 are resistant to EAE, fail to develop mononuclear
cell infiltrates, and display decreased Ag-specific proinflam-
matory responses in the secondary lymphoid organs. These
results suggest an essential nonredundant in vivo function
for CCR2 in the pathogenesis of EAE.
 
Materials and Methods
 
Mice and EAE Induction.
 
CCR2
 
2
 
/
 
2
 
 mice were generated by
homologous recombination as previously described (17).
CCR2
 
2
 
/
 
2
 
 and CCR2
 
1
 
/
 
1
 
 (WT) littermate controls were gener-
ated from matings between heterozygous (CCR2
 
1
 
/
 
2
 
) mice (50/
50 Sv129 
 
3
 
 C57BL/6) and raised in identical specific pathogen–
free conditions. To induce EAE, CCR2
 
2
 
/
 
2
 
 and WT littermates
between 12 and 16 wk of age were immunized in the footpad
with a total of 100 
 
m
 
g of MOGp35–55 (MGH Peptide Synthesis
Facility, Charlestown, MA) emulsified in CFA (Difco Labs.);
mice also received two intraperitoneal injections of 200 ng of
Pertussis toxin (List Biological Laboratories) on days 0 and 2 after
immunization. Animals were scored for signs of EAE using the
following criteria: 1, tail paralysis; 2, hind limb weakness; 3, hind
limb paralysis; 4, hind limb plus forelimb paralysis; 5, moribund
or dead.
 
Cytokine Production and Proliferation.
 
Spleens from mice in
each group were collected on days 8, 11, 20, 23, and 26 after dis-
ease induction; popliteal LNs draining the immunization site
were collected on day 9. The organs were dispersed into a single-
cell suspension, washed, and cultured at 4 
 
3 
 
10
 
6
 
 cells/ml in se-
rum-free X-Vivo 20 medium (Biowhittaker) with 100 
 
m
 
g/ml
MOGp35–55. Supernatants were collected at 24 h for IL-2 and
IL-4, 48 h for IFN-
 
g
 
 and IL-10, 72 h for TGF-
 
b
 
 and IL-6, and
96 h for TNF-
 
a
 
. Quantitative ELISA was performed for interleu-
kins and TNF-
 
a
 
 using paired mAbs and protocol supplied by the
manufacturer (PharMingen). Active and latent (with acid activa-
tion) TGF-
 
b
 
 levels were determined by ELISA (Promega). For
proliferation, cells were cultured in triplicate at 2 
 
3 
 
10
 
6
 
 cells/ml
with various doses of MOGp35–55, anti-CD3 mAb (PharMin-
gen), or Con A (Fisher Scientific). [
 
3
 
H]Thymidine was added in
the last 16 h of a 96-h stimulation with Ag or in the last 16 h of a
48-h stimulation with anti-CD3 mAb or Con A. Plates were har-
vested and counts read using a beta counter. Values used repre-
sent the mean value of three wells.
 
CNS Histology.
 
Brains and spinal cords from mice in each
group were collected on days 8, 11, 15, 20, 23, and 26 after dis-
ease induction and fixed in 10% formalin in PBS. Paraffin-
embedded tissues were sectioned 5 
 
m
 
m thick at 60-
 
m
 
m intervals
and stained with hematoxylin and eosin as well as the myelin-spe-
cific stain Luxol fast blue. Slides were analyzed in a blinded fash-
ion for lesion activity and type of infiltrating cells.
 
RNase Protection Assay.
 
Brains from mice in each group were
collected on days 8, 11, 15, 20, 23, and 26 after disease induction
and snap frozen in liquid nitrogen. Total RNA was prepared
from frozen brain by standard guanidium isothiocyanate CsCl
 
2
 
gradient centrifugation. The RNA probes used to detect
chemokine and chemokine receptor mRNAs as well as the
GADPH control for RNA loading was generated by in vitro
transcription (PharMingen). Samples of total RNA (5 
 
m
 
g) were
hybridized with 3 
 
3
 
 10
 
5
 
 cpm/
 
m
 
l of 
 
a
 
-[
 
32
 
P]UTP (3,000 Ci/
mmol; NEN Life Science Products) labeled probe at 56
 
8
 
C over-
night. RNase A and RNase Ti (PharMingen) digestion were car-
ried at 37
 
8
 
C for 45 min. The digested products were separated on
a 5% acrylamide–8 M urea gel, which was dried and film exposed
(Eastman Kodak Co.) for 5–16 h.
 
Phagocyte Migration to the LN.
 
Mice were injected subcutane-
ously in the footpad with 100 
 
m
 
l of PBS/CFA 1:1 emulsion con-
taining 1 
 
m
 
l of FluoroSpheres of 0.5-
 
m
 
m diameter (Molecular
Probes). Popliteal LNs were collected 10 d after immunization,
specimens were frozen in TissueTek medium (Sakura), and 5-
 
m
 
m
frozen sections were made at 60-
 
m
 
m intervals. Sections were ex-
amined for fluorescence using a UV microscope.
 
Results and Discussion
 
CCR2
 
2
 
/
 
2
 
 Mice Are Resistant to Induction of EAE.
 
To
test the contribution of CCR2 signaling in the initiation
and progression of EAE, CCR2
 
2
 
/
 
2
 
 and CCR2
 
1
 
/
 
1
 
 mice
were immunized with the encephalitogenic peptide
MOGp35–55 and scored for signs of disease (Fig. 1).
MOGp35–55 is an effective encephalitogen in the suscepti-
Figure 1. Incidence of disease in CCR22/2 and wild-type (WT) mice
immunized with MOGp35–55. Groups of 5–10 mice were immunized
with MOGp35–55 in CFA and received two intraperitoneal injections of
Pertussis toxin. Results are expressed as mean disease score. This experi-
ment is representative of n 5 3. 
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ble strain C57/BL6 bearing the H-2b MHC haplotype
(20). As mice used in these experiments were littermates
generated by crossing C57BL6/Sv129 parents heterozy-
gous at the CCR2 locus, the offspring expressed H-2b and
would be expected to remain susceptible to MOGp35–55-
induced EAE. As expected, wild-type offspring developed
clinical EAE, with a mode incidence of 80%. In contrast,
their CCR2-deficient littermates completely failed to ex-
press signs of clinical disease in 24 of 26 CCR2-deficient
mice analyzed. The two CCR2-deficient mice that devel-
oped disease had significantly delayed onset and decreased
maximal disease severity compared with the wild-type lit-
termates (data not shown).
 
Paucity of Inflammatory Lesions in CCR2
 
2
 
/
 
2
 
 Mice Immu-
nized with MOGp35–55.
 
To explore the basis of resis-
tance to disease in CCR2-deficient mice, we examined the
CNS tissues from mice in both groups. On histological ex-
amination (
 
n
 
 5 
 
6 mice per group), there were numerous
meningeal and CNS parenchymal inflammatory/demyeli-
nating lesions exclusively in the wild-type mice that also
showed signs of clinical EAE (Fig. 2). These lesions con-
sisted mainly of lymphocytic and monocytic infiltrates with
few granulocytes. There were also varying degrees of op-
tic and perioptic neuritis (data not shown). In contrast,
CCR2-deficient littermates failed to develop CNS inflam-
mation, which correlated with the absence of clinical EAE
in these mice (Fig. 2).
 
CNS Chemokine and Chemokine Receptor Expression Is Not
Detected in Immunized CCR2
 
2
 
/
 
2
 
 Mice.
 
To address the
mechanism underlying the inability of CCR2
 
2
 
/
 
2
 
 mice to
produce active lesions, we examined the CNS chemokine
profile from CCR2
 
2
 
/
 
2
 
 and CCR2
 
1
 
/
 
1
 
 mice during the de-
velopment of EAE. RNase Protection assays performed on
brains from wild-type mice immunized with MOG35–55
revealed the upregulation of RANTES (regulated on acti-
vation, normal T cell expressed and secreted), IFN-induc-
ible protein 10 (IP-10), and MCP-1. Increased levels of
these chemokines were detected on day 11, peaked on days
20–23, and declined by day 26. In contrast, chemokine ex-
pression was not induced in the CNS of CCR2
 
2
 
/
 
2
 
 immu-
nized mice at all time points examined (Fig. 3 A). These
results support the notion that CCR2-bearing cells are
needed to produce an active lesion characterized by the
production of proinflammatory chemokines that amplify
the local inflammatory response.
In accordance with an increase in RANTES and MCP-1
expression in the brains of wild-type immunized mice, we
found that the expression of their receptors was also upreg-
ulated. CCR1 and CCR5 (RANTES) and CCR2 (MCP-
1) mRNA levels increased coincident with the increase of
their ligands in wild-type mice (Fig. 3 B). In contrast, no
increase in chemokine receptor expression was detected in
CCR2-deficient immunized mice. Low levels of CCR5
mRNA were seen in CCR2-deficient and in wild-type
mice before the onset of clinical disease. These results dem-
onstrate that the upregulation of CCR1, CCR2, and
CCR5 in the brains of mice with EAE requires the activity
of CCR2-expressing cells.
 
Decreased MOGp35–55-specific T Cell Responses in
CCR2
 
2
 
/
 
2
 
 Mice.
 
As CCR2-deficient mice are resistant to
developing inflammatory lesions and clinical signs of EAE,
we asked whether this is associated with alterations in the
MOGp35–55-specific immune response. To address this
question, we analyzed the phenotype of T cells generated
by immunization with MOGp35–55 in CCR2-deficient
and wild-type mice (Fig. 4). Draining LN cells from wild-
type mice showed robust proliferative responses to Ag,
with stimulation indices approximately two times higher
than in LN cells from the CCR2-deficient animals (Fig. 4).
IFN-
 
g
 
, a proinflammatory Th1 cytokine known to be in-
volved in the pathogenesis of EAE, was also decreased in
CCR2-deficient mice compared with wild-type mice (Fig.
4). Both groups secreted similar levels of IL-6 (Fig. 4).
Levels of IL-2, TNF-
 
a
 
, IL-4, and IL-10 as well as active
TGF-
 
b
 
 were undetectable in culture supernatants (data not
shown).
We also examined the phenotype of MOGp35–55-spe-
cific T cells found in the spleen at different points in the
Figure 2. Histology of CNS tissue from MOGp35–
55-immunized mice. Hematoxylin and eosin–stained,
formalin-fixed cerebellum (A and B) and spinal cord
(C and D) from CCR21/1 (A and C) and CCR22/2
mice (B and D) after immunization with MOGp35–
55. Representative (n 5 6 mice per group) perivascu-
lar inflammatory lesions (indicated by arrows) com-
posed of mononuclear cells are shown in CCR21/1
brain and spinal cord sections. Note the absence of le-
sions and inflammatory cells in the sections from the
brain and spinal cord of CCR22/2 mice. Original
magnification 2403. 
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course of disease. At days 8, 11, 20, 23, and 26 after disease
induction, splenocytes from CCR2-deficient mice also
proliferated less robustly to Ag and secreted lower levels of
IFN-
 
g
 
 and IL-6 than splenocytes from wild-type controls,
paralleling the finding of decreased Th1 expression in
draining LNs. In contrast, when cells were stimulated with
nonspecific stimuli such as Con A or the anti-CD3 mAb,
splenocytes from CCR2-deficient mice showed prolifera-
tion that was equal to that of cells from wild-type litter-
mates (data not shown). This suggests that the decreased ef-
fector responses were Ag specific and did not result from a
generalized defect in T cell activation or function. Taken
together, these observations indicate that resistance to EAE
in CCR2-deficient mice is associated with a decreased Ag-
specific Th1 effector response.
As T cell differentiation and activation in vivo involves
effective Ag presentation, we also tested whether the ob-
served differences in Ag-specific T cell responses in vitro
could result from impaired Ag presentation in the LN.
Dendritic cells are potent immunostimulatory cells found
in the T cell areas of the LN. Recent studies concerning
the origin of these cells suggest that monocytes recruited to
an inflammatory focus acquire Ag by phagocytosis and then
rapidly leave the tissue as they migrate into the LN and dif-
ferentiate into dendritic cells (21). Therefore, we asked
whether deficiency in CCR2, a key monocyte chemoat-
tractant receptor, impairs the accumulation of phagocytes
in the LN. In preliminary experiments, we found that
CCR2
 
2
 
/
 
2
 
 mice did not show decreased phagocyte migra-
tion to the LN 10 d after they were immunized with fluo-
rescent beads in CFA (data not shown). This indicates that
monocyte recruitment to the site of immunization and the
LN are not overtly impaired in the CCR2
 
2
 
/
 
2
 
 mice and
most likely do not account for the observed decreased T
cell responses.
Our observations provide functional evidence that
CCR2 signaling is essential in the inflammatory cascade
that culminates in clinical disease. These findings suggest
that MCP-1 or other CCR2 agonists, induced in the CNS
Figure 3. Chemokine and chemokine receptor expression in brains of
MOGp35–55-immunized mice. RNase Protection analysis on 5 mg of
total RNA isolated from brains of CCR21/1 and CCR22/2 animals at
the indicated times (in days) after immunization. Unprotected probe for
each chemokine (A) and each chemokine receptor (B), which run
slightly higher than protected RNA species, is indicated in the first and/
or last lane.
Figure 4. Ag-specific proliferative responses and cytokine production
by spleen and LN cells from CCR21/1 and CCR22/2 mice. Cells were
isolated on days 8, 11, 20, 23, and 26 (spleen) and day 9 (LN; pooled
from three mice per group) after disease induction and stimulated in vitro
with MOGp35–55. Proliferative responses are shown as stimulation indi-
ces for each group responding to Ag concentration of 100 mg/ml. Cyto-
kine concentration was measured from supernatants collected after 48 h
(IFN-g) or 72 h (IL-6) of in vitro culture with peptide (100 mg/ml).1079 Izikson et al. Brief Definitive Report
by activated neuroantigen-specific T cells, are necessary for
the recruitment of peripheral blood monocytes into the
brain and spinal cord. These monocytes serve to amplify
the initial local T cell–mediated response in the CNS into
an active lesion where macrophages become sufficiently
numerous and activated to digest the myelin sheath, leading
to demyelination, axonal dysfunction, and clinical manifes-
tations of disease. Our results implicating CCR2 as an im-
portant receptor mediating monocyte recruitment in vivo
are consistent with similar findings in other inflammatory
disease models characterized by macrophage tissue accumu-
lation (17, 19, 22–24).
In addition, our data suggests that CCR2 signaling en-
hances Ag-specific effector Th1 responses in vivo. Previous
in vivo studies have also found decreased Th1 immune re-
sponses in CCR22/2 mice (17–19), although the mecha-
nism for this observation has not been completely eluci-
dated. MCP-1 has been shown to directly costimulate T
cell activation in vitro, suggesting that CCR2 signaling
may directly augment T cell proliferation and cytokine se-
cretion (25, 26). Our data further the notion that CCR2
signaling plays a role in Th1 immune responses in vivo.
In summary, we demonstrate that CCR2 is required for
the pathogenesis of an organ-specific T cell and macro-
phage-mediated inflammatory disease, EAE, a model of MS.
Accordingly, the existence of MCP-1 and CCR2 gene
mutations in the human population may be important de-
terminants in the initiation and/or progression of autoim-
mune diseases, and CCR2 antagonism might represent a
potential therapeutic approach for such conditions.
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